Scios regulatory update

SCIO partner Kaken Pharmaceutical Co. Ltd. (Tokyo, Japan) filed an NDA in Japan for approval of Fiblast, SCIO's basic fibroblast growth factor, to treat recalcitrant dermal ulcers. Fiblast is a natu...